KA Imaging Makes Distribution Deal with Malaysia Based BeyMed

KA Imaging has entered into a distribution agreement with BeyMed for distribution of KA imaging innovative dual-energy imaging solution Reveal™ 35C in the Malaysian market.

“KA Imaging is excited to be growing rapidly and providing innovative diagnostic imaging solutions worldwide, this time signing a distribution agreement to cover Malaysia. BeyMed is an emerging medical solutions company with a great potential,” said Amol Karnick, President and CEO of KA Imaging.

BeyMed values offering modern, effective problem-solving through innovative technologies and strives to provide quality technology and diagnostic solutions to support radiological practices thus minimizing diagnostic errors.

Gandhi Suppiah, Managing Director of BeyMed, stated: “KA Imaging’s Reveal 35C will complement our advanced imaging technology solutions. We are excited to partner with KA Imaging to develop new imaging solutions in this part of the world.”

BeyMed has also secured proof of concept trials that will use Reveal 35C with one of the major hospitals in Kuala Lumpur as part of the imaging solutions model in Malaysia.

Reveal 35C is the world’s first and only portable dual-energy X-ray detector. The detector provides radiologists and medical professionals with three unobstructed images in a single shot with ZERO motion artifacts for better patient care. Reveal is currently being proudly used in a few clinical trials in Canada, for detecting abnormalities like lung cancer and pneumonia (including COVID-19) with great initial success.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.